Artranking Activity the Inflammatory Response Part 2 Phagocyte Response
Neurobiol Aging. 2016 Feb; 38: 56–67.
Multiplex analyte assays to characterize dissimilar dementias: encephalon inflammatory cytokines in poststroke and other dementias
Aiqing Chen
aNeurovascular Enquiry Grouping, Found of Neuroscience, Newcastle University, Campus for Ageing & Vitality, Newcastle Upon Tyne, United kingdom
bDepartment of Psychiatry, University of Cambridge School of Clinical Medicine, Cambridge Biomedical Campus, Cambridge, Britain
Arthur East. Oakley
aNeurovascular Research Group, Institute of Neuroscience, Newcastle Academy, Campus for Ageing & Vitality, Newcastle Upon Tyne, U.k.
bDepartment of Psychiatry, Academy of Cambridge School of Clinical Medicine, Cambridge Biomedical Campus, Cambridge, UK
Maria Monteiro
aNeurovascular Research Group, Establish of Neuroscience, Newcastle University, Campus for Ageing & Vitality, Newcastle Upon Tyne, UK
bDepartment of Psychiatry, University of Cambridge Schoolhouse of Clinical Medicine, Cambridge Biomedical Campus, Cambridge, Britain
Katri Tuomela
aNeurovascular Research Grouping, Institute of Neuroscience, Newcastle University, Campus for Ageing & Vitality, Newcastle Upon Tyne, Uk
bSection of Psychiatry, Academy of Cambridge Schoolhouse of Clinical Medicine, Cambridge Biomedical Campus, Cambridge, Uk
Louise M. Allan
aNeurovascular Research Group, Plant of Neuroscience, Newcastle University, Campus for Ageing & Vitality, Newcastle Upon Tyne, UK
bDepartment of Psychiatry, University of Cambridge School of Clinical Medicine, Cambridge Biomedical Campus, Cambridge, United kingdom
Elizabeta B. Mukaetova-Ladinska
aNeurovascular Inquiry Group, Constitute of Neuroscience, Newcastle University, Campus for Ageing & Vitality, Newcastle Upon Tyne, UK
bDepartment of Psychiatry, University of Cambridge School of Clinical Medicine, Cambridge Biomedical Campus, Cambridge, UK
John T. O'Brien
aNeurovascular Inquiry Group, Plant of Neuroscience, Newcastle University, Campus for Ageing & Vitality, Newcastle Upon Tyne, UK
bDepartment of Psychiatry, Academy of Cambridge School of Clinical Medicine, Cambridge Biomedical Campus, Cambridge, Great britain
Raj N. Kalaria
aNeurovascular Enquiry Grouping, Institute of Neuroscience, Newcastle University, Campus for Ageing & Vitality, Newcastle Upon Tyne, UK
bSection of Psychiatry, University of Cambridge Schoolhouse of Clinical Medicine, Cambridge Biomedical Campus, Cambridge, UK
Received 2015 May 27; Revised 2015 Oct 20; Accepted 2015 October 24.
Abstruse
Both the inflammatory potential and cognitive function reject during aging. The association between the repertoire of inflammatory biomarkers and cognitive decline is unclear. Inflammatory cytokines accept been reported to be increased, decreased, or unchanged in the cerebrospinal fluid and sera of subjects with dementia. We assessed 112 postmortem brains from subjects diagnosed with poststroke dementia (PSD), vascular dementia, mixed dementia, and Alzheimer's disease (AD), comparing those to poststroke nondemented (PSND) subjects and age-matched controls. We analyzed 5 brain regions including the gray and white matter from the frontal and temporal lobes for a panel of cytokine and/or chemokine analytes using multiplex-array assays. Of the 37 analytes, fourteen were under or near the detection limits, 7 were close to the lowest detection level, and xvi cytokines were within the linear range of the assay. We observed widely variable concentrations of C-reactive protein (CRP) and serum amyloid A at the high end (i–150 ng/mg protein), whereas several of the interleukins (IL, interferon-gamma and tumor necrosis gene) at the low cease (one–10 pg/mg). There were besides regional variations; most notable being high concentrations of some cytokines (e.m., CRP and angiogenesis panel) in the frontal white matter. Overall, we found decreased concentrations of several cytokines, including IL-1 beta (p = 0.000), IL-6 (p = 0.000), IL-7 (p = 0.000), IL-8 (p = 0.000), IL-16 (p = 0.001), interferon-inducible protein–10 (0.044), serum amyloid A (p = 0.011), and a trend in IL-1 alpha (p = 0.084) across all dementia groups compared to nondemented controls. IL-6 and IL-eight were significantly lower in dementia subjects than in nondemented subjects in every region. In item, lower levels of IL-6 and IL-8 were notable in the PSD compared to PSND subjects. Because these 2 stroke groups had comparable degree of vascular pathology, the lower product of IL-6 and IL-8 in PSD reaffirms a possible specific involvement of immunosenescence in dementia pathogenesis. In contrast, CRP was not altered between dementia and nondementia subjects or between PSD and PSND. Our study provides bear witness not just for the feasibility of tracking cytokines in postmortem brain tissue but also suggests differentially impaired inflammatory mechanisms underlying dementia including AD. There was a macerated inflammatory response, maybe reflecting immunosenescence and cognitive cloudburst, in all dementias. Strategies to enhance anti-inflammatory cytokines and boost the immune system of the brain may be beneficial for preventing cognitive dysfunction, especially after stroke.
Keywords: Crumbling, Cognitive impairment, Immunosenescence, Inflammation, Poststroke dementia, Stroke, Vascular dementia, White matter
one. Introduction
During the last decade, there has been a surge of interest in whether inflammatory and immune responses contribute to crumbling-related dementias. Both the inflammatory potential and the immune system may decline in tandem with cognitive function during aging. Yet, information technology has been difficult to draw conclusions whether inflammation is a cause, a promoter, or but a secondary phenomenon in dementing illness. A large number of studies focused on Alzheimer'southward affliction (Ad), as the almost mutual class of dementia, indicate a direct function for inflammatory and immune processes in its pathogenesis (Rafnsson et al., 2007, Schmidt et al., 2002, Schram et al., 2007, Sudduth et al., 2013, Weaver et al., 2002, Whiteley et al., 2009). However, much less is known on the modulation of inflammatory responses in other dementias including vascular or stroke-related dementias.
The inflammatory response of the body is a dynamic procedure, and the profile of cytokine responses may differ with the duration and severity of an illness (Huberman et al., 1994, Huberman et al., 1995, Jabbari Azad et al., 2014). Cytokines in blood and cerebrospinal fluid (CSF) have been reported to be increased, decreased, or unaltered in Advertizing, vascular dementia (VaD), and ischemic stroke survivors (Alvarez et al., 1996, Beridze et al., 2011, Narasimhalu et al., 2015, Schmidt et al., 2002, Singh and Guthikonda, 1997, Lord's day et al., 2009, Whiteley et al., 2012). Few population-based studies have shown that high levels of interleukin (IL) IL-6, IL-8, and C-reactive protein (CRP) are associated with poor cognitive condition, including poor performance in memory and processing speed, every bit well as cognitive decline (Baune et al., 2008, Gimeno et al., 2008, Weaver et al., 2002, Wright et al., 2006). In ischemic stroke, higher serum ILs were associated with baseline cognitive impairment (IL-eight) and subsequent cognitive decline (IL-12) (Narasimhalu et al., 2015). Clinical trials have generally failed to demonstrate a robust beneficial effect of anti-inflammatory drugs in the progression of Advertising (Hoozemans et al., 2011), implicating a complicated part of inflammation in the pathogenesis. In contrast, although most trials were negative in ischemic stroke injury, phase 2 trials with IL-1 receptor adversary and the lath spectrum anti-inflammatory agent minocycline demonstrated improved outcomes (Smith et al., 2015).
The immune organization is also a key role player in cardinal nervous system repair and maintenance that undergoes a profound remodeling process over the lifetime and has a major touch on on private'south health and survival (Boraschi and Italiani, 2014, Fulop et al., 2010, Grubeck-Loebenstein et al., 2009). Immunosenescence, or the aging immune system, is a constellation of age-related changes to the immune organisation, resulting in greater susceptibility to infection and reduced responses to infectious pathogen(s). The characteristics of immunosenescence include historic period-induced thymic cloudburst, os marrow decreased hematopoietic compartment, and increased peripheral suppressor jail cell activity. It affects both innate and adaptive immune systems (Grubeck-Loebenstein et al., 2009).
Our aim was to investigate inflammatory cytokine profiles in extracts of postmortem brain tissues from subjects with dissimilar dementias using multiplex immunoarrays. In addition to poststroke demented (PSD) and poststroke nondemented (PSND) subjects, we assessed brains from prospectively assessed dementia subjects diagnosed with VaD, mixed dementia, and AD and from age-matched controls. With emphasis on PSD, we tested the hypothesis that different dementias accept distinct profiles of cytokines compared to those without dementia.
ii. Methods
2.ane. Subjects
Encephalon tissues from a total of 112 subjects, including 21 PSND and 20 PSD, 17 VaD, eighteen mixed dementia, and 16 Advertisement, were obtained from the Newcastle Brain Tissue Resource, Newcastle Academy. In addition, we analyzed brain tissue from similar age controls (Table i). For the poststroke subjects, concluding Mini–Mental Land Examination (MMSE) and the highest and last revised Cambridge Cognition Examination (CAMCOG) bombardment scores of the relevant subjects were used to determine the cognitive profile of analyzed subjects. Thus, stroke survivors who did not meet DSM-IIIR or Four criteria for dementia and had MMSE scores >25 and CAMCOG scores >85 were designated as poststroke survivors with no dementia. In near cases, bronchopneumonia was recorded as the crusade of death.
Table 1
Demographic details and pathological features of the subjects
| Group | N | Historic period | Gender (Grand%:F%) | Braak stageb | MMSE | CAMCOG |
|---|---|---|---|---|---|---|
| Control | 20 | 79.ii ± 3.3 | 35:65 | 1.72 ± 0.32 | 28.8 ± 0.8 | na |
| PSNDa | 21 | 85.0 ± 1.0 | 57:43 | 2.48 ± 0.25 | 27.2 ± 0.4 | 89.7 ± 1.iii |
| PSDa | 20 | 87.3 ± 1.3 | thirty:seventy | ii.73 ± 0.24 | 15.ix ± one.1 | 66.2 ± 2.5 |
| VaD | 17 | 83.9 ± 1.vi | 41:59 | 1.93 ± 0.25 | xiii.four ± 3.7 | na |
| Mixed | 18 | 84.5 ± 1.2 | 44:56 | five.thirteen ± 0.22 | x.6 ± 2.36 | na |
| AD | 16 | 83.9 ± 1.9 | 56:44 | v.31 ± 0.17 | vii.four ± ane.ix | 39.1 ± half dozen.eight |
Neuropathological assessment was carried out equally described previously, using standardized protocols (Allan et al., 2011, Ihara et al., 2010, Kalaria et al., 2004). Macroscopical infarcts, detected by visual inspection while dissecting the brain, were after confirmed by light microscopy. Hematoxylin-eosin staining was used for assessment of structural integrity and infarcts, Nissl and luxol fast blue staining for cellular patterns and myelin loss, Bielschowsky's silver impregnation and amyloid β for CERAD and/or Thal rating of neuritic plaques, Gallays for neuritic pathology, and tau immunohistochemistry for Braak staging of neurofibrillary tangles. Vascular pathology scores were determined in PSND and PSD cases and controls equally described previously (Deramecourt et al., 2012).
Pathological diagnosis of AD was consistent with the National Institute on Aging–Alzheimer's Association guidelines for the neuropathological cess of Advertising (Montine et al., 2012). VaD was diagnosed every bit described previously (Kalaria et al., 2004). In PSD cases, a definite diagnosis of VaD was made when there were multiple or cystic infarcts, lacunae, microinfarcts and minor vessel disease, and Braak stage ≤4 in the presence of clinically overt cognitive impairment (Deramecourt et al., 2012, Kalaria et al., 2004). Mixed dementia was classified when there was significant vascular pathology and sufficient degree of pathology to reach Braak Five–VI, in the presence of clinically verified dementia syndrome. Tissues from control subjects had occasional aging-related pathology and were classified having "no pathological diagnosis" (Table ane). Even so, they had no strokes, transient ischemic attacks (excluded because of hypertension or cardiovascular gamble factors), or any type of dementing affliction.
two.2. Preparation of samples
Ane hundred to 150 mg frozen brain tissues from five different brain regions namely, BA9 for frontal gray thing (FGM), BA21 for temporal gray matter (TGM), the underlying frontal white affair (FWM), and temporal white affair (TWM), besides every bit hippocampus (Hipp), were dissected from each case and control. Frozen encephalon tissues were homogenized in water ice-cooled lysis buffer (3 μL per mg of tissue moisture weight, 50 mM Tris-Buffer, 150 mM NaCl, 0.05% Tween-20, pH = 7.five) with 2× phosphostease inhibitor (78,420, Thermo Scientific) and Protease inhibitor cocktail (87,786, Thermo Scientific) using the Precellys 24 tissue homogenizer (Bertin Technologies) with three cycles of xx seconds over 5 minutes interval). The homogenates were centrifuged at 10,000 rpm for threescore minutes at 4 °C. The supernatant was so collected and transferred immediately into 3 microtubes to avoid repeated freeze and thaw bicycle: ane 150 μL of sample was kept at −80 °C for multiplex array, one xx μL of sample was kept at −twenty °C for protein analysis, and the rest of the sample was stored at −eighty °C for future apply. Protein concentrations were estimated with the DC kit (500-0112, Bio-Rad).
ii.three. Multiplex arrays
On the solar day of assays, protein homogenates were thawed on water ice. We assessed 37 cytokines in each sample with the Neuroinflammation Console 1 (man) kit (Meso-Scale Discovery, K15210D). Duplicate aliquots of 150 μL of 4 mg/mL samples in lysis buffer containing ane% blocker A and one× phosphatase and protease inhibitor were prepared in a 96-well preparation plate. There were 5 mini plates for each Neuroinflammation Panel 1 (homo) kit, and each mini plate was designed for the measurement of each group of cytokines, upwards to 9 cytokines in each console (Table ii). Calibrator dilutions and samples were prepared co-ordinate to the manufacturer'due south recommendation (Table 2). The protocol for cytokine measurement is summarized in Fig. 1. Cytokine concentrations were read in the MESO QUICKPLEX SQ 120 from MSD with software DISCOVERY WORKBENCH 4.0. For those analytes beneath the lower limit of detection (LLOD, a calculated concentration corresponding to the point 2.5 standard deviations above the groundwork [nix calibrator]) and those with no-reading, the LLOD were used for private samples and cytokines. The highest concentration at which the coefficient of variation (CV) of the calculated concentration (ULOQ) was <20%, and the recovery of each calibrator was inside 80%–120% of the known value. The lowest concentration at which the CV of the calculated concentration (LLOQ) was <20%, and the recovery of each calibrator was inside 80%–120% of the known value. The quantitative range of the assay lay between the lower limit (LLOQ) and upper limit (ULOQ) values.
Flowchart of brain tissue training and analysis.
Table ii
Reagents and sample grooming of Neuroflammation Panel ane (homo) kit from MSD multispot assay system
| MSD panel kits | Analysts | Diluent for sample and calibrator | Dilution | Added volume for diluent (μL) | Sample (μL) | Diluent for detection antibiotic |
|---|---|---|---|---|---|---|
| Pronflammatory panel 1 | IFN-γ, IL-1β, IL-2, IL-4, IL-6, IL-8, IL-ten, IL-13, TNF-α | Diluent ii | one:two | 25 | 25 | Diluent 3 |
| Cytokine console i | IL-1α, IL-v, IL-7, IL-12p40, IL-fifteen, IL-16, IL-17A, TNF-β, VEGF | Diluent 43 | 1:two | 25 | 25 | Diluent 3 |
| Chemokine panel 1 | Eotaxin, MIP-1β, Eotaxin-3, TARC, IP-10, MIP-1α, MCP-1, MDC, MCP-four | Diluent 43 | i:4 | 37 | xiii | Diluent iii |
| Angiogenesis panel 1 | VEGF-C, VEGF-D, Tie-2, Flt-1, PIGF | Diluent vii | 1:2 | 25 | 25 | Diluent eleven |
| Vascular injury panel 1 | SAA, CRP, VCAM-1, ICAM-onea | Diluent 101 | i:five | xx | 5 | Diluent 101 |
| Human being bFGF Kit Five-PLEX | bFGFb | Diluent seven | 1:2 | 25 | 25 | Diluent eleven |
2.4. Statistical analysis
Statistical assay was carried out using SPSS, version 21, with the level of significance set up at p < 0.05. The demographics of the samples including age, postmortem delay (PMD), were compared with the Mann-Whitney U test. There were no statistical differences between the groups. Because these cytokine measurements are from dissimilar patients and dissimilar areas with multiple factors involved, it is inadequate to clarify them with common nonparametric tests (e.g., Isle of mann-Whitney U test), as they are unable to examine interaction effects. As such, raw information from multiplex assortment were ranked with aligned ranking transfer (Higgins and Tashtoush, 1994) (ARTool, http://depts.washington.edu/aimgroup/proj/art/), and the ranking was analyzed with one-way analysis of variance and Fisher's LSD postal service hoc tests (>three groups) or independent sample t test (2 groups) for samples from all 5 areas and individual expanse. The data were analyzed for the differences between the different patient groups from all 5 areas and from individual expanse. They were compared between unlike areas likewise to run into the area effects. Homogenate measurements were presented every bit pg/mg of total poly peptide.
3. Results
The LLODs from our experiment were within the LLOD range in the information canvas for almost all individual cytokines, except macrophage-derived chemokine, macrophage inflammatory poly peptide (MIP)-1β, and vascular endothelial growth factor (VEGF)-C (Table 2 for abbreviations). Almost recovery for each calibrator was within fourscore%–120% of the known value (data non shown). We noted predominantly similar concentration profiles of various cytokines when plotted as demented and nondemented groups or every bit PSD and PSND groups (Fig. 2A and B). The highest concentrations of the analytes were of CRP and SAA (1–150 ng/mg), whereas several of the key ILs were in low concentrations (i–10 pg/mg).
(A and B) Distribution of brain analytes in demented and control subjects. The analytes for all samples are grouped from the highest to the lowest concentrations. Red symbols correspond demented samples, and blue symbols represent nondemented sample. *Almost of the measurements are undetectable or shut to LLOD. **All measurements from FWM are all in the quantitative range of the assay, and some of the measurements from all other areas are near to LLOD. ***Most of the measurements were close to LLOQ, and some of the measurements were marginally below the LLOQ. For estimation of the analyte abbreviations, meet Table ii. (B) Encephalon analytes in poststroke demented (PSD) and nondemented (PSND) subjects.
Because Extaxin, interferon (IFN)-gamma, IL-ii, IL-five, IL-10, IL-12p40, IL-17A, monocyte chemoattractant protein–4, macrophage-derived chemokine, MIP-1 alpha, MIP-i beta, TARC, TNF-alpha, and TNF-beta were undetectable or shut to LLOD, and not in the quantitative range of the assay betwixt LLOQ and ULOQ, we did not have these analyses further. We also institute that IL-4, IL-xiii, Eotaxin-3, and VEGF needed to exist interpreted carefully because most of the measurements were close to or just below LLOQ. For Tie 2, VEGF-C, and VEGF-D, the measurements from FWM were within the quantitative range of the assay, whereas some measurements from the other regions were virtually the LLOD. Nosotros therefore concentrated on the post-obit predominantly proinflammatory cytokines: bones fibroblast growth cistron (bFGF), CRP, fms-related tyrosine kinase ane, IL-1α, IL-1β, IL-6, IL-vii, IL-8, IL-xv, IL-xvi, ICAM-i, interferon-inducible poly peptide–10, monocyte chemoattractant poly peptide–1, placenta growth factor, SAA, and VCAM-ane. Most of the analysis values for these lay in the quantitative range of the assay and considered reliable. The median and 5%–95% range of concentrations of these measurable cytokines are provided in Tabular array 3. In terms of brain regions, nosotros observed wide variations, merely the FWM often exhibited college concentrations of some of the cytokines, particularly vascular growth related factors (not shown) and CRP.
Tabular array 3
The median and 5%–95% range of measurements (pg/mg of total protein) for the detectable cytokines in PSND, PSD, nondemented (including control and PSND), and demented (including PSD, VaD, mixed dementia, and AD)
| Median (five%–95%) | Nondemented | Demented | PSND | PSD |
|---|---|---|---|---|
| Proinflammatory panel one | ||||
| IL-1β | 0.77 (0.25–two.82) | 0.63 (0.21–2.11) | 0.77 (0.29–two.39) | 0.73 (0.23–2.71) |
| IL-4 | 0.09 (0.03–0.41) | 0.08 (0.02–0.36) | 0.09 (0.02–0.33) | 0.09 (0.02–0.37) |
| IL-6 | 0.84 (0.xiii–8.75) | 0.42 (0.10–three.19) | 0.69 (0.09–vii.68) | 0.39 (0.10–1.39) |
| IL-eight | viii.47 (i.79–81.58) | 4.92 (ane.75–27.71) | half-dozen.eleven (1.51–116.09) | 4.67 (2.21–17.96) |
| IL-13 | 0.66 (0.27–ane.24) | 0.60 (0.20–0.99) | 0.63 (0.25–i.37) | 0.62 (0.23–0.94) |
| Cytokine panel 1 | ||||
| IL-1α | 3.75 (1.29–ix.50) | three.32 (i.25–viii.99) | 3.62 (1.39–9.47) | 4.21 (1.34–x.61) |
| IL-7 | 1.02 (0.40–2.ninety) | 0.85 (0.22–2.38) | 1.08 (0.27–2.48) | 0.88 (0.32–2.63) |
| IL-15 | 1.10 (0.51–2.xiv) | 1.xiii (0.49–2.24) | 1.10 (0.54–2.28) | 1.14 (0.46–two.13) |
| IL-16 | 551.34 (268.54–1032.67) | 489.37 (157.19–939.47) | 558.50 (277.44–1032.67) | 512.03 (170.91–920.59) |
| VEGF | one.84 (0.37–iv.99) | 1.49 (0.26–iii.52) | 1.59 (0.29–4.68) | 1.55 (0.42–iii.54) |
| Chemokine panel 1 | ||||
| Eotaxin3 | 7.25 (0.54–63.90) | 5.91 (0.76–50.47) | 7.63 (i.70–56.63) | half-dozen.89 (1.03–48.29) |
| IP-ten | 10.20 (iii.48–71.07) | 8.88 (ii.90–27.54) | 9.11 (3.65–156.22) | eight.49 (3.81–26.69) |
| MCP1 | nineteen.51 (half dozen.63–312.18) | 19.82 (6.83–101.38) | 18.92 (eight.21–397.51) | eighteen.25 (seven.35–77.46) |
| Angiogenesis panel 1 | ||||
| VEGF-C | threescore.68 (29.09–1144.00) | 62.xxx (32.57–1242.13) | 64.12 (29.10–1163.87) | 58.42 (29.09–1187.55) |
| VEGF-D | 4.91 (2.07–78.97) | 6.60 (ii.nineteen–86.86) | iv.91 (2.46–86.14) | six.01 (2.xxx–75.22) |
| Tie-2 | 84.83 (30.06–410.65) | eighty.67 (26.35–420.77) | 87.81 (34.49–434.40) | 95.20 (36.54–420.xv) |
| FLT-ane | 1327.51 (655.84–2475.34) | 1338.74 (726.02–2409.87) | 1369.08 (878.99–2475.82) | 1304.33 (684.08–2261.78) |
| PIGF | 4.89 (1.85–13.90) | 5.56 (2.29–14.37) | 5.36 (1.97–xiv.67) | 5.12 (2.52–xi.72) |
| bFGF | 5737.0 (3165.4–ten,483.7) | 6142.0 (3468.half-dozen–12,547.iii) | 5960.3 (3417.2–10,889.5) | 6281.8 (3701.5–thirteen,014.6) |
| Vascular injury panel i | ||||
| SAA | 4176.5 (628.7–58,673.4) | 3871.6 (608.0–56,675.eight) | 5721.2 (1000.one–80,591.ix) | 4934.4 (1067.one–48,981.4) |
| CRP | 39,603.0 (5883.iv–96,862.0) | 33,381.four (4486.4–106511) | 44,230.4 (3257.three–110510.6) | 44,845.5 (eleven,561.two–110865.6) |
| VCAM-one | 1619.7 (642.iii–4879.7) | 1694.3 (601.4–5555.9) | 1767.nine (648.5–5435.9) | 1442.three (565.3–5720.nine) |
| ICAM-1 | 1233.vii (468.0–2501.three) | 1310.4 (617.8–3307.6) | 1365.3 (670.0–2549.2) | 1179.6 (684.6–2747.0) |
iii.i. Proinflammatory cytokines in dementia
When samples were designated into the demented grouping, which included VaD, mixed, AD and PSD, and the not-demented group, which included normal controls and PSND, we noted significantly lower concentrations of cytokines overall in demented subjects (Table 3): IL-1 beta (p = 0.000), IL-6 (p = 0.000), IL-7 (p = 0.000), IL-eight (p = 0.000), IL-16 (p = 0.001), interferon-inducible protein–ten (0.044), SAA (p = 0.011), and IL-i alpha (p = 0.084). However, compared to nondemented subjects, there were higher concentrations of the following analytes in dementia: bFGF (p = 0.002), ICAM-i (p = 0.001), VEGF-C (p = 0.000), VEGF-D (p = 0.000). More interestingly, when all the samples for all encephalon regions from poststroke subjects were analyzed, relative to PSND subjects, PSD had lower concentrations of IL-6 (p = 0.000) and IL-viii (p = 0.000). In contrast, in that location were college concentrations of IL-1 alpha (p = 0.040) in PSD compared to PSND subjects.
3.two. IL-vi, IL-viii, and CRP
IL-6 and IL-viii were analyzed further to explore specificity for dementia types and regional differences based on the aforementioned findings. We reasoned that the concentrations of these cytokines and CRP might distinguish the demented and nondemented subjects, and in particular PSD and PSND groups (Fig. 3 and Table 4). We noted clear differences between demented and nondemented groups with or without stroke (Fig. 3C). Statistical analysis by one-style analysis of variance after Aligned Rank Transform (ART) showed that the normal controls had significantly college levels of IL6 and IL-8 than the affliction groups, including PSND, PSD, VaD, AD, and mixed, both when brain areas were analyzed separately, or grouped (p < 0.01). To exclude all possible stroke-induced influences (i.east., PSND and PSD subjects), only nonstroke samples were analyzed with independent sample t test later Art. It was found that nondemented samples (only controls without stroke) had higher levels of IL-half dozen (p = 0.000) and IL-8 (p = 0.000) than the entire sample of demented subjects (including Ad, mixed dementia, and VaD). Moreover, the normal controls had significantly higher levels of IL-6 and IL-8 compared to Advertising or mixed dementia or VaD (p < 0.02 for all; data non shown).
Concentrations of IL-vi, IL-8, and CRP in different dementias and brain regions. (A) Boxplots from different disease grouping in each brain region for IL-6 (a), IL-8 (b), and CRP (c). Boxplots for all samples from unlike regions: IL-6 (d), IL-eight (e), CRP (f). (B) Boxplots from different areas in each illness grouping for IL-half dozen (g), IL-8 (h), and CRP (i). Boxplots for all samples from different diseases: IL-6 (j), IL-8 (k), CRP (l). (C) Boxplots showing IL-6 (chiliad), IL-eight (northward), and CRP (o) concentrations for samples from all nondemented and demented subjects and from PSND and PSD subjects. *p < 0.05, **p < 0.005, ***p < 0.001. Abbreviations: AD, Alzheimer's disease; CRP, C-reactive protein; FGM, frontal greyness matter; FWM, frontal white affair; IL, interleukin; PSD, poststroke demented; PSND, poststroke nondemented; TGM, temporal gray thing; TWM, temporal white matter; VaD, vascular dementia.
Table 4
Significance by one-way ANOVA exam afterward ART ranking for all samples from each brain area and for all v brain areas of demented and nondemented subjects
| Brain regions and test groups | IL-6 | IL-eight | |
|---|---|---|---|
| FGM | Demented vs. nondemented | 0.013 | 0.014 |
| FWM | Demented vs. nondemented | 0.005 | 0.023 |
| TGM | Demented vs. nondemented | 0.004 | 0.003 |
| TWM | Demented vs. nondemented | 0.002 | 0.037 |
| Hipp | Demented vs. nondemented | 0.017 | 0.026 |
| All areas | Demented vs. nondemented | 0.000 | 0.000 |
Between each illness group, statistical analysis showed that controls had higher concentrations of IL-6 than all other groups (p < 0.001, Supplementary Tabular array ane). The PSND grouping also showed college levels of IL-6 than PSD, VaD, and mixed dementia subjects, but non dissimilar from Advert (Fig. threeG). Control and PSND subjects also had significantly higher concentrations of IL-viii than PSD, VaD, and mixed dementia groups, whereas no differences were apparent between control and PSND subjects (Supplementary Table ane, Fig. iiiH). Although Advertizing subjects showed significantly lower concentrations of IL-8 than controls, at that place was no difference with the PSND grouping. There were also no differences in the concentrations of both IL-vi and IL-eight between PSD, VaD, and mixed dementia; however, at that place was a difference between Ad and PSD for IL-6 (p = 0.006) and a trend in IL-eight (p = 0.061). When analysis was express to comparing of Advertising and normal controls, independent sample t tests (afterward Fine art) showed that AD subjects exhibited lower concentrations of both IL-half-dozen (p = 0.001) and IL-8 (p = 0.019) compared to controls.
The concentrations of IL-6 were like between the dissimilar brain areas analyzed, with exception of the TWM, which had significantly lower IL-6 in relation to FGM, TGM, and hippocampus (Hipp) (Fig. 3D). The white affair IL-viii content (both FWM and TWM) was significantly lower to that plant in the gray matter (FGM, TGM, and Hipp). There were no differences found between FGM, TGM, and Hipp or between FWM and TWM (Fig. 3E). We also noted significant (p < 0.05) correlations between IL-half-dozen and IL-8 concentrations and the MMSE and CAMCOG scores across all dementias and in all poststroke subjects (Supplementary Table 2).
CRP was not significantly altered between demented and nondemented groups (p = 0.257), or between PSD and PSND subjects (p = 0.l). However, CRP was significantly college in PSD compared to VaD, mixed, Ad, and control (Fig. 350). The FWM had significantly lower levels of CRP than all the other brain areas (Fig. 3F).
4. Discussion
Our study represents the kickoff multiplex analyte assay in a big number of postmortem encephalon tissues from unlike dementias. The specificity of our results was demonstrated not simply past the quantitative analyte changes but as well by the varied regional distribution of several cytokines. Overall, we plant decreases in many cytokines within both the gray and white thing across all dementia subtypes, suggesting inflammatory or allowed factors are noteworthy substrates contributing to the pathogenesis of dementia per sé, irrespective of their underlying pathological changes.
We provide reliable estimates of private cytokine concentrations in relation to brain protein in human brain tissues. They range from very loftier concentrations, for instance, CRP, SAA, and bFGF to just barely detectable levels such as those of IFN-gamma, TNF-alpha, and TNF-beta. Because the periods of PMD were comparable between the dementia groups and controls, we surmise that postmortem alterations for whatever cytokine would be to a similar degree across samples. Therefore, the relative changes we observed between dementia samples and groups would be valid, particularly that the cytokine assays were performed on the same occasion.
Virtually previous studies were performed in trunk fluids, primarily plasma (or sera) and CSF quantified as weight per unit volumes (Brosseron et al., 2014, Hu et al., 2012, Lee et al., 2009, Swardfager et al., 2010). Although it is not entirely adequate to compare cytokine concentrations between brain tissues and those reported previously in plasma and CSF samples, it may be of relevance here to consider the often studied cytokines such as IL-6 and IL-8. In a recent report (Leung et al., 2013), the median (range) plasma concentrations of IL-half dozen and IL-8 in elderly controls were reported to exist eight.nine (i.three–36.half dozen) and 8.three (1.nine–31.3) pg/mL. With reference to the CSF, the median concentrations of IL-vi and IL-eight, in normal elderly subjects in another study (Westhoff et al., 2013), were reported to exist 1.0 (0.2–2.2) and 28.4 (22.7–42.v) pg/mL, respectively. Given that widely published values for total protein in 1 mL of plasma and i mL CSF contain approximately 70 (60–80) and 0.45 (0.2–0.six) mg/mL protein, respectively (Felgenhauer, 1974), the aforementioned median (and range) concentrations of IL-6 in plasma reported by Leung et al. (2013) calculate to 0.13 (0.02–0.52) pg/mg protein, whereas that in CSF reported past Westhoff et al. (2013) calculate to 2.2 (0.44–4.9) pg/mg protein. Similarly, for IL-eight, normal elderly plasma contains approximately 0.12 (0.03–0.45) pg/mg poly peptide and CSF approximates to 63.1 (50.five–94.iv) pg/mg protein. The values for CSF of 1.seven (0.7–14.8) and 34.9 (17.5–64.2) pg/mL for these cytokines reported by Kern et al. (2014) likewise fall within a comparable range. These calculations signal that compared to plasma, CSF has greater amounts of both IL-6 and IL-8, and in that location is a 20-25 fold difference between these cytokines in the CSF but about similar amounts in the plasma. Although nosotros establish a >7-fold difference in concentrations of these 2 cytokines within the brain, we report generally lower concentrations of IL-eight per mg protein, in particular, compared to the recently published CSF concentrations (Kern et al., 2014, Westhoff et al., 2013). The highest brain values of IL-6 and IL-8 were determined to be viii.9 and forty.0 pg/mg poly peptide, respectively. Various factors could contribute to these differences. Because the total CSF protein in older (>70 years) than younger people (0.two–0.half dozen mg/mL) is generally greater, we suggest the mean concentrations nosotros recorded in brain are realistic.
We specifically noted decreased concentrations of both IL-6 and IL-8 in encephalon tissues of demented subjects. As PSD and PSND subjects in our accomplice had similar survival periods after stroke and exhibited comparable degrees of vascular burden (Allan et al., 2011), the lower production of IL-6 and IL-eight in PSD suggests a specific change related to a gene(s) which contribute to dementia per sé. When samples from stroke patients (PSND and PSD) were excluded from the cohort, all other forms of dementia also showed significantly lower levels of IL-6 and IL-8 than the normal controls, implying a possible similar diminished immune response in the context of dementia including AD. The origin of IL-6 in the brain is uncertain, with a number of studies hinting that neurons, glial cells, and the vascular endothelium could exist the source of IL-vi (Jang et al., 2008, Suzuki et al., 2009). Indeed, immunostaining with IL-6 antibody was constitute within neuronal and glial cells in formalin stock-still encephalon tissue sections (Air conditioning and RNK, data not shown). Although IL-6 is involved in the synthesis of acute phase proteins, it displays pleiotrophic effects (Frei et al., 1989). IL-6 was also shown to be essential for poststroke angiogenesis (Gertz et al., 2012) and a protectant of cerebral infarction (Herrmann et al., 2003, Loddick et al., 1998). IL-half-dozen height in CSF of stroke patients and its further correlation with stroke severity have been reported in some studies (Beridze et al., 2011, Vila et al., 2000) although Sunday et al. (2009) did not find any change in IL-6 in the CSF. Plasma elevated concentrations of IL-6, IL-1 beta, and TNF-alpha have too been reported in the elderly (Kern et al., 2014). Although this seems to contradict the expected functional defects, chronic subclinical inflammation may be caused by partial inability of the aged immune system to eliminate sure pathogens, such as products of degradation processes implicating an inefficient immune response in the elderly.
Our results are consistent with some previous findings, reporting decreases in IL-6 in the brain tissues from the frontal grey and white matter of VaD and mixed dementia in comparison to controls (Mulugeta et al., 2008). Kim et al. (2011) reported significantly lower plasma IL-8 levels in subjects with balmy cerebral damage and AD than controls. Similar findings of meaning decreases in TNF-alpha and IL-6 in CSF and serum, respectively, were reported in AD subjects with a mean duration of dementia for two.5 years (1.five–iii.4 years) (Richartz et al., 2005). Yamada et al. (1995) as well reported decreased CSF IL-6 in Advertising, with the magnitude of CSF IL-6 reduction significantly greater in early on onset dementia. However, serum concentrations of some proteins may increase initially but decline in later M2 stages of disease like AD, every bit elegantly demonstrated by Sudduth et al. (2013). In our cohort, most AD patients had astringent degree of dementia, with MMSE score lower than 8, which may bespeak that they are more frail and exhibit more intense immunosenesence.
In Advert, higher levels of cytokines (IL-half-dozen and IFN-gamma) were reported in lymphocytes, and these were related to more than avant-garde age (Jabbari Azad et al., 2014). Similarly, in another study (Licastro et al., 2000), higher concentrations of IL-half dozen in peripheral blood of AD subjects were reported, merely this was not evident in the CSF (Engelborghs et al., 1999). Baune et al. (2008) reported that increased serum concentrations of IL-8 were associated with poor cognitive operation on cognitive tests in healthy elderly individuals. These inconsistent findings in the context of our findings in postmortem brain tissue may be attributed to differences in study populations, for case, inclusion criteria of subjects (different degrees of pathogenesis), sample size, and different protocols for sample blazon and preparation and variability in analysis procedures. For virtually of the studies, cytokines were sampled from peripheral blood (serum, plasma, or whole blood cells) or CSF and often have short half-lives. They may attain college concentrations at or near sites of release and much lower concentrations later on dilution into blood and CSF.
Remarkably, when whole blood supernatants were stimulated by lipopolysaccharide (bacterial virulence factors that induce inflammation), there was a macerated product of proinflammatory cytokines (TNF-α and IL-1β) in older people compared to younger individuals (Bruunsgaard et al., 1999). This lack of response in cytokine production on stimulation reflects the general dysfunction of detail immune cells on inflammatory stimuli, indicating the presence of immunosenescence, with an adulterate secretory activity for IL-half-dozen, IL-12, IFN-gamma, TNF-alpha of monocytes and/or macrophages within whole blood cell cultures of AD subjects. This suggests a systemic, possibly age-related alteration of allowed mechanisms involved in AD pathogenesis (Richartz et al., 2005). De Luigi et al. (2002) found that dementia patients exhibited an upregulation of circulating cytokines and a downregulation of cytokines released past blood cells after exposure to lipopolysaccharide, suggesting a similar mechanism is present in both AD and multi-infarct dementia. In add-on, there is further prove of premature immunosenescence with decreased T- and B-jail cell numbers and insufficient microglial phagocytosis in AD subjects (Richartz-Salzburger et al., 2007). Thus, better cognitive performance was associated with less effector memory CD4+ T cells, more naïve CD8+ T cells, and more B cells in healthy elderly people. In dissimilarity, significantly lower levels of CD4+ naïve T cells and an increase in the ratio of the activated and/or naïve CD4+ T cells were establish in Advert subjects (Tan et al., 2002). It is not unlikely there are shared pathways leading to cognitive dysfunction amid various types of dementia. Immunosenescence could be one possible crusade, promoter, or outcome of dementia pathology. Alternatively, they occur simultaneously and are interrelated and interact with each other (De Luigi et al., 2002).
The dampening of the inflammatory and/or immune responses in relation to pathological changes may non only occur in Ad, but also in other types of dementias, such as VaD and PSD every bit evident from our written report. This phenomenon has been linked to other diseases. For example, the percentages of CD8+ naïve and CD8+ recent thymic emigrant cells, and T-cell receptor rearrangement excision circumvolve levels in peripheral claret cells were significantly lower in cancer patients than in historic period-matched controls (Falci et al., 2013). Cancer patients also accept significant shorter telomere lengths and significant lower level of CRP and IL-six and nutritional markers in their peripheral blood samples, when compared to the controls (Falci et al., 2013). It is plausible that subjects destined to develop dementia accept a diminished inflammatory response, encompassing immunosenescence. These subjects who are more often than not frail develop greater susceptibility to infection but reduced responses and impaired elimination of pathogens (Boraschi and Italiani, 2014, Grubeck-Loebenstein et al., 2009). Although more testify needs to be gathered to demonstrate that immunosenescence causes dementia, studies using strategies to rejuvenate the immune organization partially take demonstrated memory recovery in allowed-deficient mice (Ron-Harel et al., 2008).
There are some limitations to our written report. It is possible that the long postmortem interval could take contributed to related global or differential changes in cytokines. The cause of death and antemortem status including whatever comorbidities could be additional factors influencing the observed results. The main cause of death in our sample was bronchopneumonia (Allan et al., 2011). Notwithstanding, there was also no correlation betwixt cytokine levels and PMD, as indicated by multiple regression analysis, and there were no differences in PMD between the groups. We also could not delineate whatever of the groups from controls based on any known antemortem comorbidities. We would expect all brain regions to have been affected as, merely clearly, there were differential responses in cytokines. Another factor is that prior medications could take modulated the cognitive expression of cytokines. Nevertheless, as previously reported, all subjects had similar use of medication in respect to their mental and physical health (Allan et al., 2011).
Our study provides potent evidence of impaired inflammatory mechanisms in the pathogenesis of dementia. It is possible that the decreased inflammatory response reflects cellular changes in reactive cells or simply global encephalon atrophy related to dementia. Further assessment of jail cell specific markers of microglia and astrocyte markers could demonstrate whether there are any changes in reactive cells and whether the decreased cytokine levels were considering of dampened cellular responses. The investigation of inflammatory markers in bloods from the same cohort may exist of further utilise. Better agreement of the association between the immune system and cognitive function volition help u.s. to develop new strategies to counter against cognitive dysfunction.
Disclosure statement
The coauthors take no disclosures with regard to this report. The study was not industry sponsored. There are no conflicts of involvement.
Acknowledgements
The authors are grateful to the patients, families, and clinical business firm staff for their cooperation in the investigation of this study. The authors give thanks Michelle Widdrington, Carein Todd, Jean Scott, Deborah Lett, and Anne Nicholson for assistance in managing and screening the cohort. The authors thank Janet Y Slade and Roslyn Hall for excellent technical aid. The authors are about grateful to the staff of the Newcastle Brain Tissue Resource (NBTR) for profitable u.s. to undertake this complicated study. The authors would like to acknowledge the profound support of Meso-Scale Discovery (MSD) (Dr John Butler and Dr James Parry). This work is primarily supported by a grant from the Dunhill Medical Trust United kingdom of great britain and northern ireland (R277/0213). The authors also acknowledge connected support of the Medical Inquiry Quango (MRC, G0500247), Newcastle Centre for Brain Ageing and Vitality (BBSRC, EPSRC, ESRC and MRC, LLHW), and Alzheimer'south Enquiry (ARUK). The CogFAST study was originally supported by the MRC in 1999. Tissue for this study was nerveless by the Newcastle Brain Tissue Resource, which is funded in part by a grant from the Great britain MRC (G0400074), past the Newcastle NIHR Biomedical Research Heart in Ageing and Age Related Diseases honour to the Newcastle Upon Tyne Hospitals NHS Foundation Trust, and by a grant from the Alzheimer's Society and ARUK as part of the Brains for Dementia Inquiry Project.
Aiqing Chen led the study, performed most of the described experiments, adult relevant methodology, undertook the assay, and wrote the first typhoon of the article. Arthur E. Oakley advised on and interpreted the morphological analysis, constructed the figures, and corrected drafts of the commodity. Maria Monteiro assisted with the retrieval and dissection of the brain tissues used in the study. Katri Tuomela assisted with the setup and functioning of the multiplex assays. Louise Allan provided clinical input to the CogFAST study, participated in diagnostic consensus conferences, and gave intellectual support. Elizabeta Mukaetova-Ladinska provided intellectual advice on the study and corrected drafts of the commodity. John T. O'Brien clinical input to the CogFAST written report, participated in diagnostic consensus conferences, and gave intellectual back up. Raj Northward. Kalaria conceived the original study, performed some of the neuropathological assay, corrected several drafts, and obtained the funding.
Footnotes
Appendix A. Supplementary data
Supplementary Tables 1 and 2:
References
Allan L.M., Rowan Eastward.N., Firbank M.J., Thomas A.J., Parry Southward.W., Polvikoski T.M., O'Brien J.T., Kalaria R.N. Long term incidence of dementia, predictors of bloodshed and pathological diagnosis in older stroke survivors. Encephalon. 2011;134(Pt 12):3716–3727. [PMC complimentary article] [PubMed] [Google Scholar]
Alvarez 10.A., Franco A., Fernandez-Novoa L., Cacabelos R. Blood levels of histamine, IL-1 beta, and TNF-alpha in patients with mild to moderate Alzheimer disease. Mol. Chem. Neuropathol. 1996;29:237–252. [PubMed] [Google Scholar]
Baune B.T., Ponath Thou., Golledge J., Varga G., Arolt V., Rothermundt Grand., Berger K. Association between IL-8 cytokine and cognitive performance in an elderly general population—the MEMO-Study. Neurobiol. Crumbling. 2008;29:937–944. [PubMed] [Google Scholar]
Beridze M., Sanikidze T., Shakarishvili R., Intskirveli Northward., Bornstein North.M. Selected astute phase CSF factors in ischemic stroke: findings and prognostic value. BMC Neurol. 2011;11:41. [PMC free article] [PubMed] [Google Scholar]
Boraschi D., Italiani P. Immunosenescence and vaccine failure in the elderly: strategies for improving response. Immunol. Lett. 2014;162(1 Pt B):346–353. [PubMed] [Google Scholar]
Brosseron F., Krauthausen Grand., Kummer Grand., Heneka M.T. Body fluid cytokine levels in mild cognitive damage and Alzheimer'south affliction: a comparative overview. Mol. Neurobiol. 2014;50:534–544. [PMC complimentary article] [PubMed] [Google Scholar]
Bruunsgaard H., Pedersen A.North., Schroll Thou., Skinhoj P., Pedersen B.Chiliad. Impaired production of proinflammatory cytokines in response to lipopolysaccharide (LPS) stimulation in elderly humans. Clin. Exp. Immunol. 1999;118:235–241. [PMC free article] [PubMed] [Google Scholar]
De Luigi A., Pizzimenti S., Quadri P., Lucca U., Tettamanti M., Fragiacomo C., De Simoni M.Thousand. Peripheral inflammatory response in Alzheimer'southward disease and multiinfarct dementia. Neurobiol. Dis. 2002;11:308–314. [PubMed] [Google Scholar]
Deramecourt 5., Slade J.Y., Oakley A.Eastward., Perry R.H., Ince P.G., Maurage C.A., Kalaria R.N. Staging and natural history of cerebrovascular pathology in dementia. Neurology. 2012;78:1043–1050. [PMC complimentary article] [PubMed] [Google Scholar]
Engelborghs S., De Brabander M., De Cree J., D'Hooge R., Geerts H., Verhaegen H., De Deyn P.P. Unchanged levels of interleukins, neopterin, interferon-gamma and tumor necrosis factor-alpha in cerebrospinal fluid of patients with dementia of the Alzheimer type. Neurochem. Int. 1999;34:523–530. [PubMed] [Google Scholar]
Falci C., Gianesin K., Sergi M., Giunco S., De Ronch I., Valpione Due south., Solda C., Fiduccia P., Lonardi S., Zanchetta 1000., Keppel S., Brunello A., Zafferri V., Manzato Due east., De Rossi A., Zagonel V. Immune senescence and cancer in elderly patients: results from an exploratory study. Exp. Gerontol. 2013;48:1436–1442. [PubMed] [Google Scholar]
Felgenhauer K. Protein size and cerebrospinal fluid composition. Klinische Wochenschrift. 1974;52:1158–1164. [PubMed] [Google Scholar]
Frei K., Malipiero U.V., Leist T.P., Zinkernagel R.1000., Schwab M.E., Fontana A. On the cellular source and office of interleukin vi produced in the central nervous system in viral diseases. Eur. J. Immunol. 1989;nineteen:689–694. [PubMed] [Google Scholar]
Fulop T., Kotb R., Fortin C.F., Pawelec 1000., de Angelis F., Larbi A. Potential role of immunosenescence in cancer development. Ann. N. Y. Acad. Sci. 2010;1197:158–165. [PubMed] [Google Scholar]
Gertz K., Kronenberg Thou., Kalin R.E., Baldinger T., Werner C., Balkaya Grand., Eom G.D., Hellmann-Regen J., Krober J., Miller K.R., Lindauer U., Laufs U., Dirnagl U., Heppner F.Fifty., Endres Grand. Essential role of interleukin-6 in mail service-stroke angiogenesis. Encephalon. 2012;135(Pt 6):1964–1980. [PMC free article] [PubMed] [Google Scholar]
Gimeno D., Marmot M.Chiliad., Singh-Manoux A. Inflammatory markers and cerebral office in middle-anile adults: the Whitehall II study. Psychoneuroendocrinology. 2008;33(10):1322–1334. [PMC costless article] [PubMed] [Google Scholar]
Grubeck-Loebenstein B., Della Bella Southward., Iorio A.M., Michel J.P., Pawelec One thousand., Solana R. Immunosenescence and vaccine failure in the elderly. Crumbling Clin. Exp. Res. 2009;21:201–209. [PubMed] [Google Scholar]
Herrmann O., Tarabin Five., Suzuki S., Attigah N., Coserea I., Schneider A., Vogel J., Prinz S., Schwab S., Monyer H., Brombacher F., Schwaninger Thousand. Regulation of body temperature and neuroprotection past endogenous interleukin-6 in cerebral ischemia. J. Cereb. Blood Menses Metab. 2003;23:406–415. [PubMed] [Google Scholar]
Higgins J.J., Tashtoush S. An aligned rank transform test for interaction. Nonlinear World. 1994;ane:201–211. [Google Scholar]
Hoozemans J.J., Veerhuis R., Rozemuller J.Chiliad., Eikelenboom P. Soothing the inflamed encephalon: issue of not-steroidal anti-inflammatory drugs on Alzheimer's disease pathology. CNS Neurol. Disord. Drug Targets. 2011;ten:57–67. [PubMed] [Google Scholar]
Hu W.T., Holtzman D.M., Fagan A.Thou., Shaw 50.M., Perrin R., Arnold South.E., Grossman M., Xiong C., Craig-Schapiro R., Clark C.M., Pickering E., Kuhn M., Chen Y., Van Deerlin V.M., McCluskey L., Elman L., Karlawish J., Chen-Plotkin A., Hurtig H.I., Siderowf A., Swenson F., Lee V.M., Morris J.C., Trojanowski J.Q., Soares H., Alzheimer's Affliction Neuroimaging Initiative Plasma multianalyte profiling in mild cerebral impairment and Alzheimer disease. Neurology. 2012;79:897–905. [PMC free article] [PubMed] [Google Scholar]
Huberman One thousand., Shalit F., Roth-Deri I., Gutman B., Brodie C., Kott E., Sredni B. Correlation of cytokine secretion by mononuclear cells of Alzheimer patients and their disease stage. J. Neuroimmunol. 1994;52:147–152. [PubMed] [Google Scholar]
Huberman G., Sredni B., Stern L., Kott East., Shalit F. IL-2 and IL-6 secretion in dementia: correlation with blazon and severity of disease. J. Neurol. Sci. 1995;130:161–164. [PubMed] [Google Scholar]
Ihara M., Polvikoski T.Thousand., Hall R., Slade J.Y., Perry R.H., Oakley A.East., Englund E., O'Brien J.T., Ince P.G., Kalaria R.Due north. Quantification of myelin loss in frontal lobe white matter in vascular dementia, Alzheimer's disease, and dementia with Lewy bodies. Acta Neuropathol. 2010;119:579–589. [PMC gratuitous article] [PubMed] [Google Scholar]
Jabbari Azad F., Talaei A., Rafatpanah H., Yousefzadeh H., Jafari R., Talaei A., Farid Hosseini R. Association betwixt cytokine production and affliction severity in Alzheimer'due south illness. Iran J. Allergy Asthma Immunol. 2014;xiii:433–439. [PubMed] [Google Scholar]
Jang Southward., Kelley Chiliad.W., Johnson R.W. Luteolin reduces IL-6 product in microglia by inhibiting JNK phosphorylation and activation of AP-1. Proc. Natl. Acad. Sci. U. S. A. 2008;105:7534–7539. [PMC free article] [PubMed] [Google Scholar]
Kalaria R.N., Kenny R.A., Ballard C.G., Perry R., Ince P., Polvikoski T. Towards defining the neuropathological substrates of vascular dementia. J. Neurol. Sci. 2004;226:75–80. [PubMed] [Google Scholar]
Kern S., Skoog I., Borjesson-Hanson A., Blennow Chiliad., Zetterberg H., Ostling Southward., Kern J., Gudmundsson P., Marlow T., Rosengren L., Waern One thousand. Higher CSF interleukin-6 and CSF interleukin-8 in current depression in older women. Results from a population-based sample. Brain Behav. Immun. 2014;41:55–58. [PubMed] [Google Scholar]
Kim S.M., Song J., Kim S., Han C., Park Chiliad.H., Koh Y., Jo S.A., Kim Y.Y. Identification of peripheral inflammatory markers between normal control and Alzheimer'southward disease. BMC Neurol. 2011;xi:51. [PMC complimentary article] [PubMed] [Google Scholar]
Lee K.S., Chung J.H., Choi T.K., Suh Southward.Y., Oh B.H., Hong C.H. Peripheral cytokines and chemokines in Alzheimer'due south illness. Dement. Geriatr. Cogn. Disord. 2009;28:281–287. [PubMed] [Google Scholar]
Leung R., Proitsi P., Simmons A., Lunnon K., Guntert A., Kronenberg D., Pritchard One thousand., Tsolaki Grand., Mecocci P., Kloszewska I., Vellas B., Soininen H., Wahlund 50.O., Lovestone Due south. Inflammatory proteins in plasma are associated with severity of Alzheimer's affliction. PLoS One. 2013;8:e64971. [PMC free article] [PubMed] [Google Scholar]
Licastro F., Pedrini S., Caputo 50., Annoni Grand., Davis L.J., Ferri C., Casadei V., Grimaldi L.M. Increased plasma levels of interleukin-1, interleukin-vi and blastoff-one-antichymotrypsin in patients with Alzheimer'south affliction: peripheral inflammation or signals from the brain? J. Neuroimmunol. 2000;103:97–102. [PubMed] [Google Scholar]
Loddick S.A., Turnbull A.V., Rothwell N.J. Cerebral interleukin-half dozen is neuroprotective during permanent focal cognitive ischemia in the rat. J. Cereb. Blood Flow Metab. 1998;xviii:176–179. [PubMed] [Google Scholar]
Montine T.J., Phelps C.H., Beach T.Yard., Bigio E.H., Cairns Due north.J., Dickson D.West., Duyckaerts C., Frosch M.P., Masliah E., Mirra S.Southward., Nelson P.T., Schneider J.A., Thal D.R., Trojanowski J.Q., Vinters H.V., Hyman B.T., National Plant on Crumbling. Alzheimer's Association National Plant on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease: a practical approach. Acta Neuropathol. 2012;123:i–xi. [PMC free commodity] [PubMed] [Google Scholar]
Mulugeta Eastward., Molina-Holgado F., Elliott G.Due south., Hortobagyi T., Perry R., Kalaria R.N., Ballard C.G., Francis P.T. Inflammatory mediators in the frontal lobe of patients with mixed and vascular dementia. Dement. Geriatr. Cogn. Disord. 2008;25:278–286. [PubMed] [Google Scholar]
Narasimhalu K., Lee J., Leong Y.Fifty., Ma Fifty., De Silva D.A., Wong Thousand.C., Chang H.M., Chen C. Inflammatory markers and their clan with postal service stroke cerebral decline. Int. J. Stroke. 2015;x:513–518. [PubMed] [Google Scholar]
Rafnsson S.B., Deary I.J., Smith F.B., Whiteman M.C., Rumley A., Lowe Yard.D., Fowkes F.G. Cognitive decline and markers of inflammation and hemostasis: the Edinburgh Artery Study. J. Am. Geriatr. Soc. 2007;55:700–707. [PubMed] [Google Scholar]
Richartz E., Batra A., Simon P., Wormstall H., Bartels 1000., Buchkremer Chiliad., Schott Thousand. Diminished production of proinflammatory cytokines in patients with Alzheimer'south disease. Dement. Geriatr. Cogn. Disord. 2005;xix:184–188. [PubMed] [Google Scholar]
Richartz E., Stransky Due east., Batra A., Simon P., Lewczuk P., Buchkremer G., Bartels G., Schott Grand. Refuse of immune responsiveness: a pathogenetic gene in Alzheimer'due south illness? J. Psychiatr. Res. 2005;39(5):535–543. [PubMed] [Google Scholar]
Richartz-Salzburger East., Batra A., Stransky E., Laske C., Kohler N., Bartels G., Buchkremer G., Schott K. Altered lymphocyte distribution in Alzheimer's disease. J. Psychiatr. Res. 2007;41:174–178. [PubMed] [Google Scholar]
Ron-Harel North., Segev Y., Lewitus Thou.M., Cardon One thousand., Ziv Y., Netanely D., Jacob-Hirsch J., Amariglio North., Rechavi G., Domany East., Schwartz M. Age-dependent spatial memory loss tin be partially restored by immune activation. Rejuvenation Res. 2008;11:903–913. [PubMed] [Google Scholar]
Schmidt R., Schmidt H., Curb J.D., Masaki K., White L.R., Launer L.J. Early on inflammation and dementia: a 25-year follow-up of the Honolulu-Asia Aging Study. Ann. Neurol. 2002;52:168–174. [PubMed] [Google Scholar]
Schram M.T., Euser Due south.M., de Craen A.J., Witteman J.C., Frolich M., Hofman A., Jolles J., Breteler 1000.K., Westendorp R.G. Systemic markers of inflammation and cognitive turn down in old age. J. Am. Geriatr. Soc. 2007;55:708–716. [PubMed] [Google Scholar]
Singh V.K., Guthikonda P. Circulating cytokines in Alzheimer'south affliction. J. Psychiatr. Res. 1997;31:657–660. [PubMed] [Google Scholar]
Smith C.J., Denes A., Tyrrell P.J., Di Napoli M. Phase II anti-inflammatory and immune-modulating drugs for acute ischaemic stroke. Practiced Opin. Investig. Drugs. 2015;24:623–643. [PubMed] [Google Scholar]
Sudduth T.L., Schmitt F.A., Nelson P.T., Wilcock D.One thousand. Neuroinflammatory phenotype in early Alzheimer'due south disease. Neurobiol. Aging. 2013;34:1051–1059. [PMC gratis article] [PubMed] [Google Scholar]
Sun Y., Lu C.J., Lin C.H., Wen 50.L. Interleukin-1beta is increased in the cerebrospinal fluid of patients with small infarcts. Eur. J. Neurol. 2009;16:858–863. [PubMed] [Google Scholar]
Suzuki S., Tanaka K., Suzuki North. Ambivalent aspects of interleukin-vi in cerebral ischemia: inflammatory versus neurotrophic aspects. J. Cereb. Blood Menstruum Metab. 2009;29:464–479. [PubMed] [Google Scholar]
Swardfager W., Lanctot K., Rothenburg 50., Wong A., Cappell J., Herrmann North. A meta-assay of cytokines in Alzheimer's disease. Biol. Psychiatry. 2010;68:930–941. [PubMed] [Google Scholar]
Tan J., Town T., Abdullah L., Wu Y., Placzek A., Minor B., Kroeger J., Crawford F., Richards D., Mullan M. CD45 isoform amending in CD4+ T cells as a potential diagnostic marker of Alzheimer'due south disease. J. Neuroimmunol. 2002;132:164–172. [PubMed] [Google Scholar]
Vila N., Castillo J., Davalos A., Chamorro A. Proinflammatory cytokines and early neurological worsening in ischemic stroke. Stroke. 2000;31:2325–2329. [PubMed] [Google Scholar]
Weaver J.D., Huang Grand.H., Albert K., Harris T., Rowe J.W., Seeman T.E. Interleukin-6 and risk of cognitive pass up: MacArthur studies of successful aging. Neurology. 2002;59:371–378. [PubMed] [Google Scholar]
Westhoff D., Witlox J., Koenderman Fifty., Kalisvaart One thousand.J., de Jonghe J.F., van Stijn K.F., Houdijk A.P., Hoogland I.C., Maclullich A.M., van Westerloo D.J., van de Beek D., Eikelenboom P., van Gool West.A. Preoperative cerebrospinal fluid cytokine levels and the gamble of postoperative delirium in elderly hip fracture patients. J. Neuroinflammation. 2013;10:122. [PMC free commodity] [PubMed] [Google Scholar]
Whiteley Westward., Chong Due west.L., Sengupta A., Sandercock P. Blood markers for the prognosis of ischemic stroke: a systematic review. Stroke. 2009;40:e380–e389. [PubMed] [Google Scholar]
Whiteley W., Wardlaw J., Dennis Chiliad., Lowe Chiliad., Rumley A., Sattar N., Welsh P., Green A., Andrews M., Sandercock P. The use of blood biomarkers to predict poor result after acute transient ischemic attack or ischemic stroke. Stroke. 2012;43:86–91. [PubMed] [Google Scholar]
Wright C.B., Sacco R.L., Rundek T., Delman J., Rabbani L., Elkind M. Interleukin-6 is associated with cognitive role: the Northern Manhattan Study. J. Stroke Cerebrovasc. Dis. 2006;15:34–38. [PMC free commodity] [PubMed] [Google Scholar]
Yamada Grand., Kono G., Umegaki H., Yamada 1000., Iguchi A., Fukatsu T., Nakashima N., Nishiwaki H., Shimada Y., Sugita Y., Yamamoto T., Hasegawa T., Nabeshima T. Decreased interleukin-six level in the cerebrospinal fluid of patients with Alzheimer-type dementia. Neurosci. Lett. 1995;186:219–221. [PubMed] [Google Scholar]
Source: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4759608/
0 Response to "Artranking Activity the Inflammatory Response Part 2 Phagocyte Response"
Post a Comment